Company Overview
Company Type: Public Company
Website: www.certara.com
Number of Employees: 1,177
Ticker: CERT (NasdaqGS)
Year Founded: 2008


Business Description
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Financial Information (Currency: CAD, in mm) 
Total Revenue
483.7
Market Capitalization
3,094.8
TEV/Total Revenue
6.6x
EBITDA
135.2
Total Enterprise Value
3,169.3
TEV/EBITDA
22.3x
EBIT
61.7
Cash & ST Invst.
344.6
P/Diluted EPS Before Extra
117.6x
Net Income
26.3
Total Debt
419.1
Price/Tang BV
NM
Capital Expenditure
(1.6)
Total Assets
2,159.8
Total Debt/EBITDA
2.9x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
0.15
-
0.62
0.60 - 0.66
0.62
Revenue (mm)
118.48
-
485.96
473.94 - 494.55
487.36
EBITDA (mm)
41.42
-
170.49
164.85 - 175.84
169.89

Forward Multiples (Current FY)

Price/Earnings
31.01x
TEV/REV
6.52x
TEV/EBITDA
18.59x
PEG
0.72x
P/BV
1.99x

Non-Periodic Estimates

Recommendation
Outperform (2.25)
Target Price
26.30
Potential Upside
35.76%
LT Growth (%)
43.33%


Key Professionals
Name
Title
Feehery, William F.
CEO & Director
Pedersen, Leif E.
President & Chief Commercial Officer
Gallagher, John E.
Chief Financial Officer
Kanevsky, Max 
Chief Technology Officer
Rostami, Amin
Chief Scientific Officer
Traynor, Richard M.
Senior VP, General Counsel & Secretary
DiSantis, Ron 
Senior Vice President of Corporate Development
Rocchio, Sheila 
Chief Marketing Officer
Sherman, Nicolette D.
Chief Human Resources Officer
Aspbury, Robert P.
President of Certara Scientific Software
Bois, Frederic Yves
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Jones, Hannah 
Senior VP & Head of PBPK Consulting Services

Key Board Members
Name
Title
Cashman, James E.
Independent Chairman of the Board
Feehery, William F.
CEO & Director
Bois, Frederic Yves
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Broshy, Eran 
Independent Director
Killefer, Nancy 
Independent Director
Rowland, Malcolm 
Chair of Simcyp Scientific Advisory Board
Walsh, Matthew M.
Independent Director
Collins, Cynthia L.
Independent Director
Crane, Rosemary A.
Independent Director
Dressman, Jennifer B.
Member of Simcyp Scientific Advisory Board
Houston, J Brian
Member of Simcyp Scientific Advisory Board
Lesko, Lawrence J.
Member of Simcyp Scientific Advisory Board


Primary Industry Classification
Health Care Technology


Primary Office Location
100 Overlook Center Suite 101 | Princeton, NJ | 08540 | United States
Phone: 609 716 7900   

Current and Pending Investors
Arsenal Capital Partners (David Spaight), Eqt Partners A/S, EQT Partners AB, Fifteenth Investment Company LLC, Howard Hughes Medical Institute, Kirkbi Invest A/S, Mamoura Diversified Global Holding PJSC, Mubadala Investment Company PJSC, Santo Holding (Deutschland) GmbH

Prior Investors
Arsenal Capital Partners III, L.P., EQT Avatar Parent L.P., Sampension Private Equity F.M.B.A., Vector Capital Management, L.P. (Thomas Smith)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 19.60
Market Cap (mm)
3,094.8
Open
 19.34
Shares Out. (mm)
159.8
Previous Close
 19.37
Float %
67.4%
Change on Day
0.23
Shares Sold Short (mm)
6.0
Change % on Day
1.2%
Dividend Yield %
-
Day High/Low
 19.62/ 19.03
Diluted EPS Excl. Extra Items
0.16
52 wk High/Low
 34.29/ 14.56
P/Diluted EPS Before Extra
116.66x
Volume (mm)
0.15
Avg 3M Dly Vlm (mm)
0.73
Beta 5Y
1.47


 
Delayed Quote** | Last Updated on Oct-05-2023 01:52 PM (GMT-5)


Index Membership
S&P 600;S&P Composite 1500;S&P 600 Health Care Equipment & Services (Industry Group);S&P 600 Health Care (Sector);S&P 1000;S&P Completion Index (CI);S&P 600 - Health Care Technology (Industry);S&P 600 - Health Care Technology (Sub Ind);S&P TMI Index;S&P SmallCap 600 Value;S&P 1000 Value;S&P SmallCap 600 Growth;S&P 1000 Growth;S&P Composite 1500 - Health Care Technology (Industry);S&P Composite 1500 - Health Care Technology (Sub Ind);S&P Composite 1500 Health Care (Sector);S&P Composite 1500 Health Care Equipment & Services (Industry Group);S&P Composite 1500 Growth;S&P Composite 1500 Value;S&P Americas Under USD3 Billion Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed Between USD2 Billion and USD10 Billion Index;S&P Americas BMI Health Care Equipment & Services (Industry Group) Index;S&P Americas SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Americas SmallCap Growth Index;S&P Americas Between USD1 Billion and USD5 Billion Index;S&P Americas Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Australia Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Australia BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed Between USD1 Billion and USD5 Billion Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Canada SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Canada Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Switzerland Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Australia SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Eurozone Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.K. Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Canada SmallCap Health Care (Sector) Index;S&P Developed Ex-Europe Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Eurozone BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Under USD3 Billion Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-Japan Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-Canada Under USD3 Billion Index;S&P Developed Ex-Europe BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Global Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Pan Asia Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-Switzerland SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Canada Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Canada SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Europe SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Pan Asia BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-Switzerland Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Global BMI Index;S&P Global BMI Health Care Equipment & Services (Industry Group) Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Health Care Equipment & Services (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America BMI Health Care Equipment & Services (Industry Group) Index;S&P North America SmallCap Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P North America BMI Index;S&P Global SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Global Ex-Japan SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Global Ex-Pan Asia Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P United States BMI Index;S&P United States SmallCap Health Care Equipment & Services (Industry Group) Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America SmallCap Health Care (Sector) Index;S&P North America SmallCap Health Care Equipment & Services (Industry Group) Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P United States BMI Growth Health Care (Sector) Index;S&P United States BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P United States Between USD1 Billion and USD5 Billion Index;S&P United States BMI Growth Index;S&P United States SmallCap Growth Index;S&P United States Under USD3 Billion Index;S&P North America Between USD2 Billion and USD10 Billion Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P United States SmallCap Growth Health Care (Sector) Index;S&P United States Between USD2 Billion and USD10 Billion Index;S&P United States BMI Health Care Equipment & Services (Industry Group) Index;S&P United States SmallCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Canada BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Canada SmallCap Growth Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.K. SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan Between USD2 Billion and USD10 Billion Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P North America Between USD1 Billion and USD5 Billion Index;S&P North America SmallCap Growth Index;S&P United States SmallCap Index;S&P North America BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Canada BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Japan BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Europe BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P United States BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-Switzerland BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Health Care Equipment & Services (Industry Group)  Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care;S&P SmallCap 600 Equal Weighted Health Care (US Dollar);S&P SmallCap 600 Equal Weighted Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Health Care Equipment & Services (Industry Group) Index;S&P Developed Ex-Israel BMI Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Israel BMI Between USD2 Billion and USD10 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Americas Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Australia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Canada Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Europe Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Eurozone Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Israel Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Switzerland Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Pan Asia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P North America Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P United States Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex. Japan SmallCap Growth Health Care Equipment & Services (Industry Group);S&P 1000 Health Care (Sector);S&P 1000 Health Care Equipment & Services (Industry Group);S&P 1000 Health Care Technology (Industry);S&P 1000 Health Care Technology (Sub-Industry);S&P United States SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Europe SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Canada SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Israel SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Israel BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Australia SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-U.K. SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Eurozone SmallCap Growth Health Care Equipment & Services (Industry Group);S&P North America SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Global Ex-Australia & New Zealand Between USD1 Billion and USD5 Billion;S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-Korea SmallCap;S&P Developed BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Asia Pacific BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Europe BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Japan BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Australia BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Eurozone BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Switzerland BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Japan SmallCap Growth Health Care Equipment & Services (Industry Group);S&P United States BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Canada BMI Growth Health Care Equipment & Services (Industry Group);S&P North America BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-UK BMI Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-UK SmallCap Growth Health Care Equipment & Services (Industry Group);S&P Developed Ex-Korea BMI Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Drug Interaction Solutions
Drug Interaction Solutions develops and provides Drug Interaction Database (DIDB) to support pharmaceutical researchers, regulatory scientists, and clinicians in their evaluation of PK-based drug interactions and drug safety. The company was founded in 1999 and is based in Seattle, Washington. As of June 20, 2023, Drug Interaction Solutions operates as a subsidiary of Certara, Inc.

United States and Canada
Health Care Technology
-
-
-
Vyasa Analytics, LLC
Vyasa Analytics, LLC develops a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. The company was incorporated in 2016 and is based in Newburyport, Massachusetts. As of December 28, 2022, Vyasa Analytics, LLC operates as a subsidiary of Certara, Inc.

United States and Canada
Health Care Technology
4.00
-
-
Integrated Nonclinical Development Solutions, Inc.
Integrated Nonclinical Development Solutions, Inc. provides drug development consulting services. The company offers drug development support services ranging from target selection to product registration. It provides toxicology services, including nonclinical safety program design and management, due diligence, and regulatory submission preparation, as well as focus on areas, such as cardiovascular, central nervous system, oncology, inflammation, dermatology, infectious disease, and women's health. The company also specializes in the areas of general, genetic, and inhalation toxicology; and safety pharmacology, clinical pathology, carcinogenicity, impurity issues, biologics/biotherapeutics, natural products/herbal medicines, hazard notifications, material safety data sheets, statistics/data evaluation, process improvement, dispensary/formulations, vehicle safety, pediatric drugs, and study monitoring. In addition, it provides technology services, such as data warehousing, automated reporting, portal development, and study management. The company was founded in 2007 and is based in Ann Arbor, Michigan. Integrated Nonclinical Development Solutions, Inc. operates as a subsidiary of Certara, Inc. As of January 5, 2022, Integrated Nonclinical Development Solutions, Inc. operates as a subsidiary of Certara, Inc.

United States and Canada
Health Care Services
-
-
-
Pinnacle 21, LLC.
Pinnacle 21, LLC. provides software and services for preparing clinical trial data for regulatory submission. It offers validation and issue management solutions; Define.xml Designer, a solution for creating .xml file document automatically, and enables users to manage and edit files directly like a spreadsheet; and a tool that automates users content aggregation and formatting. The company was incorporated in 2011 and is based in Montgomery, Pennsylvania. Pinnacle 21, LLC. operates as a subsidiary of Certara, Inc.

United States and Canada
Application Software
12.00
-
-
AUTHOR! et al BV
AUTHOR! et al BV provides medical writing services and data analysis support for pharmaceutical and biotechnical companies throughout Europe and the United States. Its medical writing services include regulatory writing, medical publications & education, pharmacovigilance, data disclosure, medical devices, submission readiness, quality control, and redacting. The company also provides statistics and programming services, including statistical consulting, statistical analyses, statistical programming, CDISC, meta-analysis and data-integration, data safety monitoring board, safety databases, and validation/QC services. The company was founded in 1998 and is based in Hilversum, the Netherlands with an additional office in Chesbrough. AUTHOR! et al BV operates as a subsidiary of Certara, Inc.

Europe
Life Sciences Tools and Services
-
-
-
Pirana Software & Consulting BV
Pirana Software & Consulting BV develops a pharmacometrics modeling workbench that provides modelers with structure, tools, and a graphical user interface to facilitate the processes used to create pharmacometric models and perform simulations. The company was founded in 2007 and is based in the Netherlands. Pirana Software & Consulting BV operates as a subsidiary of Certara, Inc.

Europe
Application Software
-
-
-
Analytica Laser
Analytica Laser offers consulting, research, and data services to biopharma, medical device, and public health sectors. The company was founded in 1997 and is based in London, United Kingdom. Analytica Laser operates as a subsidiary of Certara, Inc.

Europe
Research and Consulting Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-20-2023
Jun-20-2023
Merger/Acquisition
Buyer
Drug Interaction Solutions
Certara, Inc. (NasdaqGS:CERT)
University of Washington
8.34
Jan-04-2023
Dec-28-2022
Merger/Acquisition
Buyer
Vyasa Analytics, LLC
Certara, Inc. (NasdaqGS:CERT)

29.28
Nov-07-2022
Dec-08-2022
Merger/Acquisition
Target
Certara, Inc. (NasdaqGS:CERT)
Arsenal Capital Partners
EQT Avatar Parent L.P.
449.32
Aug-11-2022
Aug-11-2022
Public Offering
Target
Certara, Inc. (NasdaqGS:CERT)

Santo Holding (Deutschland) GmbH,Kirkbi Invest A/S,EQT Avatar Parent L.P. Seller Funds:Monte Rosa Opportunities, Sicav-Sif - Monte Rosa Real Estate Debt Ii
124.25
May-19-2022
-
Shelf Registration
Target
Certara, Inc. (NasdaqGS:CERT)

Santo Holding (Deutschland) GmbH,Kirkbi Invest A/S,Eqt Partners A/S Seller Funds:Monte Rosa Opportunities, Sicav-Sif - Monte Rosa Real Estate Debt Ii
858.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-13-2023
Company Conference Presentations
Certara, Inc. Presents at Baird's Global Healthcare Conference 2023, Sep-13-2023 03:45 PM
Sep-12-2023
Company Conference Presentations
Certara, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 05:30 PM
Aug-09-2023
Earnings Calls
Certara, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Aug-09-2023
Corporate Guidance - New/Confirmed
Certara, Inc. Updates Earnings Guidance for the Year 2023
Aug-08-2023
Strategic Alliances
Certara, Inc. and Xybion Digital Inc. Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & Efficacy

Competitors
AbCellera Biologics Inc. (NasdaqGS:ABCL), Evotec SE (XTRA:EVT), ICON Public Limited Company (NasdaqGS:ICLR), Metrum Research Group LLC, R Foundation, Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX), Schrödinger, Inc. (NasdaqGS:SDGR), Simulations Plus, Inc. (NasdaqGS:SLP)

M&A Advisors
Centerview Partners UK LLP, DLA Piper LLP (US), Jefferies LLC, Morgan, Lewis & Bockius LLP, Osborne Clarke LLP, Simpson Thacher & Bartlett LLP, William Blair & Company, L.L.C.


Advisors
Most Recent Auditor
RSM & Co
M&A Advisors
Centerview Partners UK LLP, DLA Piper LLP (US), Jefferies LLC, Morgan, Lewis & Bockius LLP, Osborne Clarke LLP, Simpson Thacher & Bartlett LLP, William Blair & Company, L.L.C.
Public Offering Advisors
CohnReznick LLP, Simpson Thacher & Bartlett LLP


Most Recent Auditor
RSM & Co.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:23 AM
CERT
Certara Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 03:36 AM
CERT
ValuEngine Rating and Forecast Report for CERT
Reports
11
CFRA Equity Research

Oct 01, 2023 10:46 AM
CERT
Certara, Inc.
Reports
9
New Constructs, LLC

Sep 29, 2023 08:12 PM
CERT
CERT: Forensic Stock Earnings & Valuation
Reports
6
Plunkett Research, Ltd.
Plunkett Research Team
Sep 19, 2023 04:46 AM
CERT
Certara Inc: Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within Its Industry
EPS Estimates*
63
Marktfeld
Paraskevopoulos, Michail
Sep 18, 2023 12:46 AM
CERT
Certara Inc: Peer Group Analytics - Q2 FY2023
Reports
34
Quant IP GmbH
Quant IP Research Team
Sep 13, 2023 06:00 PM
CERT
Quant IP Competitive Technology Report Certara-Inc 2023-09-01
Reports
24
GlobalData

Sep 13, 2023 04:07 AM
CERT
Certara Inc (CERT.NASD) - Financial Analysis Review
Reports
277
Smart Insider Ltd.

Sep 12, 2023 10:51 PM
CERT
Certara Inc: 1 director
Reporting Results*
1
Marktfeld
Paraskevopoulos, Michail
Sep 08, 2023 04:12 AM
CERT
Certara Inc (CERT.US): Investor Targeting - September 2023
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Arsenal Capital Partners

36,345,835

22.75

707.3

Dec-08-2022


BlackRock, Inc.

14,490,262

9.07

282.0

Jun-30-2023


The Vanguard Group, Inc.

12,621,560

7.90

245.6

Jun-30-2023


Mubadala Investment Company PJSC

9,615,384

6.02

187.1

Mar-28-2023


Baillie Gifford & Co.

9,391,977

5.88

182.8

Jun-30-2023


William Blair Investment Management, LLC

7,229,608

4.52

140.7

Jun-30-2023


ClearBridge Investments, LLC

4,147,862

2.60

80.7

Jun-30-2023


ArrowMark Colorado Holdings, LLC

4,108,089

2.57

79.9

Jun-30-2023


JP Morgan Asset Management

3,699,805

2.32

72.0

Jun-30-2023


T. Rowe Price Group, Inc.

3,370,662

2.11

65.6

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Wasatch Advisors LP
2,686,675
2,686,675
Nationwide Fund Advisors
2,993,552
1,069,340
First Trust Advisors LP
1,490,814
1,030,333
The Vanguard Group, Inc.
12,621,560
599,389
Morgan Stanley, Investment Banking and Brokerage Investments
1,031,847
570,597

Top Sellers
Sellers
Common Stock Equivalent Held
Change
FMR LLC
890,163
(2,063,234)
ArrowMark Colorado Holdings, LLC
4,108,089
(1,244,447)
Riverbridge Partners, LLC
2,976,281
(1,211,188)
Alkeon Capital Management, LLC
0
(1,106,786)
Emerald Advisers, LLC
0
(956,035)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Advanced Publication Planning and Writing Support Services, BaseCase, Cardiac Safety Simulator, Clinical Pharmacology Services, CODEx, Drug Development and Regulatory Strategy Services, Empirical PK/PD Biosimulation Platform, GlobalSubmit, Market Access Services, Mechanistic Biosimulation Platform, Model-Based Meta-Analysis Services, Pinnacle 21 Data Exchange, Pinnacle 21 Enterprise, Regulatory Writing and Medical Communications Services, Scientific Informatics Platform, Secondary Intelligence, Simcyp Discovery Simulator, Software Implementation Services, Software Maintenance Services, Software Training Services, Strategic Consulting Service, Submission Management Services, SYBYL-X Molecular Modeling and Simulation Suite, Transparency and Disclosure Services, Trial Simulator Software


Upcoming Events
Date/Time
Type
Nov-07-2023
Company Conference Presentations
Nov-07-2023
Conferences
Nov-07-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-09-2023
Jun-30-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
10-Q
12 MB
Aug-09-2023
Aug-09-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
8-K (2.02)
544 KB
May-25-2023
May-23-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
8-K (5.07, 9.01)
175 KB
May-08-2023
Mar-31-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
10-Q
8 MB
May-08-2023
May-08-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
8-K (2.02, 9.01)
709 KB
Apr-10-2023
-
Certara, Inc. (NasdaqGS:CERT)
SEC
DEFA14A
376 KB
Apr-10-2023
-
Certara, Inc. (NasdaqGS:CERT)
SEC
DEF 14A
9 MB
Mar-31-2023
Mar-29-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
8-K (5.02, 9.01)
157 KB
Mar-01-2023
Dec-31-2022
Certara, Inc. (NasdaqGS:CERT)
SEC
10-K
14 MB
Mar-01-2023
Mar-01-2023
Certara, Inc. (NasdaqGS:CERT)
SEC
8-K (2.02, 9.01)
945 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Broshy, Eran  (Independent Director)
Aug-21-2023 - Aug-22-2023
Common Shares
5,000
108,606
Open Market Acquisition
53.42
Form 4
-
Aug-21-2023
Common Shares
193
4,269
Open Market Acquisition
-
Form 4
-
Aug-22-2023
Common Shares
4,807
104,337
Open Market Acquisition
-
Form 4
Sherman, Nicolette D. (Chief Human Resources Officer)
Aug-01-2023
Common Shares
(1,057)
(28,271)
Sale to Issuer
(8.68)
Form 4
Aspbury Ph.D., Robert P. (President of Certara Scientific Software)
Jun-30-2023
Common Shares
(862)
(21,540)
Sale to Issuer
(0.32)
Form 4
Broshy, Eran  (Independent Director)
May-23-2023
Common Shares
9,360
0
Derivative Exercise and Retained Stock
New
Form 4
Crane MBA, Rosemary A. (Independent Director)
May-23-2023
Common Shares
9,324
0
Derivative Exercise and Retained Stock
New
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Cashman, James E.
Independent Chairman of the Board
609 716 7900
-

Feehery, William F.
CEO & Director
609 716 7900
-

Bois, Frederic Yves
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
609 716 7900
-
-
Broshy, Eran 
Independent Director
609 716 7900
-

Killefer, Nancy 
Independent Director
609 716 7900
-

Rowland, Malcolm 
Chair of Simcyp Scientific Advisory Board
-
-
-
Walsh, Matthew M.
Independent Director
609 716 7900
-

Collins, Cynthia L.
Independent Director
609 716 7900
-

Crane, Rosemary A.
Independent Director
609 716 7900
-

Dressman, Jennifer B.
Member of Simcyp Scientific Advisory Board
609 716 7900
-

Houston, J Brian
Member of Simcyp Scientific Advisory Board
-
-
-
Lesko, Lawrence J.
Member of Simcyp Scientific Advisory Board
609 716 7900
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Feehery, William F.
CEO & Director
609 716 7900
-

Pedersen, Leif E.
President & Chief Commercial Officer
609 716 7900
-

Gallagher, John E.
Chief Financial Officer
609 716 7900
-

Kanevsky, Max 
Chief Technology Officer
609 716 7900
-

Rostami, Amin
Chief Scientific Officer
-
-
-
Traynor, Richard M.
Senior VP, General Counsel & Secretary
609 716 7900
-
richard.traynor@certara.com
DiSantis, Ron 
Senior Vice President of Corporate Development
609 716 7900
-

Rocchio, Sheila 
Chief Marketing Officer
609 716 7900
-

Sherman, Nicolette D.
Chief Human Resources Officer
609 716 7900
-

Aspbury, Robert P.
President of Certara Scientific Software
609 716 7900
-

Bois, Frederic Yves
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
609 716 7900
-
-
Jones, Hannah 
Senior VP & Head of PBPK Consulting Services
609 716 7900
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
